<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
<url><loc>https://www.pharmawire.org/</loc><lastmod>2026-11-16T07:00:00.000Z</lastmod><changefreq>hourly</changefreq><priority>1.0</priority></url>
<url><loc>https://www.pharmawire.org/latest-news</loc><lastmod>2026-11-16T07:00:00.000Z</lastmod><changefreq>hourly</changefreq><priority>0.9</priority></url>
<url><loc>https://www.pharmawire.org/rare-disease-market-insights</loc><changefreq>weekly</changefreq><priority>0.8</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs</loc><changefreq>weekly</changefreq><priority>0.8</priority></url>
<url><loc>https://www.pharmawire.org/fda-calendar</loc><lastmod>2026-11-16</lastmod><changefreq>daily</changefreq><priority>0.8</priority></url>
<url><loc>https://www.pharmawire.org/deal-tracker</loc><lastmod>2026-11-16</lastmod><changefreq>daily</changefreq><priority>0.8</priority></url>
<url><loc>https://www.pharmawire.org/about</loc><changefreq>monthly</changefreq><priority>0.4</priority></url>
<url><loc>https://www.pharmawire.org/section/deals</loc><changefreq>daily</changefreq><priority>0.6</priority></url>
<url><loc>https://www.pharmawire.org/section/clinical</loc><changefreq>daily</changefreq><priority>0.6</priority></url>
<url><loc>https://www.pharmawire.org/section/regulatory</loc><changefreq>daily</changefreq><priority>0.6</priority></url>
<url><loc>https://www.pharmawire.org/section/markets</loc><changefreq>daily</changefreq><priority>0.6</priority></url>
<url><loc>https://www.pharmawire.org/section/legal</loc><changefreq>daily</changefreq><priority>0.6</priority></url>
<url><loc>https://www.pharmawire.org/section/policy</loc><changefreq>daily</changefreq><priority>0.6</priority></url>
<url><loc>https://www.pharmawire.org/section/business</loc><changefreq>daily</changefreq><priority>0.6</priority></url>
<url><loc>https://www.pharmawire.org/section/public-health</loc><changefreq>daily</changefreq><priority>0.6</priority></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-made-10bn-offer-for-obesity-drugmaker-rhythm-sources-say</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/albertsons-ordered-to-pay-900mn-for-fueling-washington-state-opioid-epidemic</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/indian-regulators-order-sun-pharma-to-halt-eye-care-drug-production-at-assam-plant</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/abbvie-raises-annual-profit-forecast-as-immunology-drugs-fuel-growth</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eli-lilly-raises-revenue-forecast-as-weight-loss-drug-demand-surges</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-readies-rare-muscular-dystrophy-launch-as-fda-decision-looms</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/teva-halts-mid-stage-study-of-neurodegenerative-disorder-drug</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sanofi-signals-appetite-for-bigger-deals-as-new-chief-lifts-growth-targets</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-heart-drug-failure-leaves-doctors-seeking-evidence-for-genetic-cholesterol-target</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-targets-15bn-in-annual-savings-as-pipeline-optimism-lifts-shares</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bayer-wins-first-roundup-trial-since-supreme-court-ruling</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alnylam-shares-plunge-as-uncertainty-clouds-its-transthyretin-franchise</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/surgery-partners-to-be-taken-private-in-57bn-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-stomach-cancer-drug-extends-survival-in-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/mankind-pharma-profit-jumps-on-demand-for-chronic-drugs</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/china-approves-bayer-blood-thinner-asundexian</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/cipla-misses-profit-forecasts-as-us-weakness-offsets-strong-indian-growth</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-revenue-nearly-triples-as-heart-drug-attruby-drives-narrower-loss</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-books-22bn-hit-from-drug-trial-setbacks-but-raises-guidance</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/mark-cubans-five-step-plan-to-rein-in-healthcare-costs-takes-aim-at-drug-middlemen</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/hengrui-profit-jumps-89-per-cent-on-licensing-income</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alnylam-steps-up-lobbying-as-medicare-drug-pricing-fight-intensifies</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/zealand-pharma-strikes-ai-obesity-deal-with-generate-worth-up-to-12bn</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/vanda-puts-social-anxiety-drug-on-hold-after-late-stage-trial-failure</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-strikes-40mn-ai-drug-discovery-deal-with-insitro</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alnylam-alny-faces-cardiology-test-as-rivals-heart-drug-failure-clouds-outlook</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sanofi-avoids-fine-as-eu-accepts-pledge-to-stop-disparaging-rival-flu-vaccine</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/revolution-medicines-wins-eu-committee-backing-for-pancreatic-cancer-drug</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-ends-mid-stage-fabhalta-trial-in-serious-kidney-condition</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/rare-disease-market-insights/thyroid-eye-disease-tepezza-hearing-loss-litigation-and-a-newly</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-claims-real-world-edge-for-heart-drug-over-rival-tafamidis</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/rare-disease-market-insights/spinal-muscular-atrophy-zolgensma-spinraza-and-evrysdi-compared-and-the</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/rare-disease-market-insights/sickle-cell-disease-gene-therapy-pricing-access-and-the-market-outlook</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/rare-disease-market-insights/duchenne-muscular-dystrophy-treatments-market-size-and-the-elevidys</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/rare-disease-market-insights/attr-cm-transthyretin-amyloid-cardiomyopathy-market-size-vyndamax</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/lillys-obesity-pill-wins-eu-regulatory-backing</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/galderma-to-buy-us-skincare-group-zo-skin-health-for-15bn</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/zealand-and-roche-obesity-drug-delivers-up-to-92-per-cent-weight-loss-in-mid-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/argenx-shares-tumble-after-halt-to-sjgrens-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/gsk-to-invest-more-than-800mn-in-pennsylvania-biopharma-hub</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-widens-use-of-novartis-hives-drug-easing-pipeline-concerns</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/nobel-winning-therapy-shows-early-promise-in-blind-patients</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/biomarin-shares-slip-as-pipeline-update-fails-to-impress</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/steris-doubles-down-on-healthcare-consumables-with-21bn-xodus-purchase</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bristol-myers-lung-drug-succeeds-at-lower-dose-in-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/viatris-bets-on-non-opioid-pain-drugs-with-165bn-pacira-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/securities-fraud-scrutiny-clouds-alnylams-premium-valuation</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/biomarin-cuts-117-jobs-in-california-as-it-consolidates-its-footprint</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bayer-to-invest-22bn-in-new-ohio-pharmaceutical-site</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/grails-cancer-blood-test-nears-landmark-fda-approval-but-insurance-coverage-looms</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-turns-to-hip-hop-to-raise-awareness-of-rare-heart-disease</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/florida-sues-pfizer-and-its-chief-executive-over-covid-19-vaccine-marketing</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/csl-pays-355mn-upfront-for-alentis-kidney-drug-in-deal-worth-up-to-16bn</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sanofi-and-regeneron-expand-alliance-in-8bn-deal-and-settle-litigation</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/abbvie-joins-us-pilot-to-test-new-drug-discount-rebate-model</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-bets-on-chinas-abogen-in-78bn-mrna-licensing-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/four-largest-pbms-now-control-three-quarters-of-us-drug-benefit-market-ama-finds</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/roche-signs-drug-discovery-pact-with-atavistik-bio-worth-up-to-2bn</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/innocare-strikes-335bn-research-deal-with-eli-lilly</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/mirums-hepatitis-delta-drug-cuts-viral-levels-in-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/mercks-experimental-eye-drug-matches-standard-of-care-in-diabetic-macular-edema-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-approves-abbvies-once-daily-parkinsons-pill-from-87bn-cerevel-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-bets-on-four-launches-by-2027-as-attruby-nears-blockbuster-status</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/nanexa-more-than-doubles-on-novo-nordisk-injectables-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/florida-sues-insulin-makers-and-middlemen-over-price-rises</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ascendis-slides-as-novo-rights-revert-and-execution-risk-grows</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/adarx-jumps-in-nasdaq-debut-after-upsized-ipo</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/dr-reddys-secures-india-rights-to-takedas-dengue-vaccine-qdenga</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-and-daiichi-win-nhs-backing-for-breast-cancer-drug-enhertu</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebios-acoramidis-beats-rival-drug-in-real-world-heart-study</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/gm9accj26cjko9z1c2s1m5mm7gspd7</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/us-approves-lillys-inluriyo-verzenio-combination-for-advanced-breast-cancer</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/roches-lunsumio-clears-late-stage-hurdle-in-follicular-lymphoma</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/telix-to-buy-germanys-itm-isotope-in-165bn-radiopharma-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/rwt1cuz79ijigqgkvn4gjzgbugbpkl</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/us-weighs-preserving-most-pharma-licensing-deals-with-china</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sh4iwtyx7wbavxoiecv5ckv2yb8klv</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-and-daiichis-enhertu-lung-cancer-bid-clouded-by-survival-setback</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/abbvies-qulipta-cuts-menstrual-migraine-days-in-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ge-healthcare-in-talks-to-buy-sofie-biosciences-for-about-1bn</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/akeso-and-summits-lung-cancer-drug-extends-survival-beyond-keytruda</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/us-states-step-up-antitrust-assault-on-pharmacy-benefit-managers</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-investor-calls-for-board-overhaul-after-trial-setbacks-trigger-record-share-fall</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebios-achondroplasia-pill-shows-benefits-beyond-growth-in-phase-3-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazenecas-breast-cancer-pill-falls-short-in-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/gsk-to-close-dresden-vaccine-plant-putting-641-jobs-at-risk</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/apollo-in-20-billion-talks-to-acquire-jampj-orthopedics-unit</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ionis-pharmaceuticals-prices-first-approved-alexander-disease-therapy-at-285000-per-dose</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/hc-wainwright-reiterates-buy-on-bridgebio-pharma-after-esc-trial-data</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/aspen-targets-124mn-in-african-mounjaro-sales-as-glp-1-market-surges</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/abbvie-blood-cancer-therapy-cuts-disease-progression-risk-by-60-in-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/cipla-and-qilu-strike-deal-to-challenge-mercks-keytruda-ahead-of-patent-cliff</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bubs-australia-wins-permanent-fda-clearance-for-infant-formula-shares-surge</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ultragenyx-shares-collapse-after-angelman-syndrome-drug-fails-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-cholesterol-drug-failure-clouds-lpa-treatment-race</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/spire-healthcare-agrees-to-1bn-takeover-by-private-consortium</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/louisiana-sues-express-scripts-over-alleged-drug-price-manipulation</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/gsk-to-push-mrna-flu-vaccine-into-late-stage-trial-after-mid-stage-data-show-stronger-immune-response</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-approves-takeda-and-protagonists-rusfertide-for-rare-blood-cancer-ending-decades-of-reliance-on-bloodletting</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-hutchmed-drug-combination-shows-promise-in-advanced-lung-cancer-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazenecas-attr-cm-trial-failure-raises-broader-questions-about-silencer-drugs</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/kimberly-clark-seeks-eu-approval-for-40bn-kenvue-acquisition</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-approves-gileads-once-daily-combination-pill-for-suppressed-hiv-patients-1</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eli-lilly-to-acquire-merida-biosciences-for-up-to-288bn-in-autoimmune-push</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-pauses-eight-clinical-trials-of-experimental-cell-therapy-after-three-patient-deaths</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/jazzs-ziihera-records-second-survival-win-in-her2-positive-stomach-cancer</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebios-attruby-shows-evidence-of-disease-reversal-in-long-term-heart-study</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/pharma-giants-double-down-on-ai-in-race-to-slash-drug-development-costs</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/florida-sues-pbms-over-alleged-pharmacy-price-fixing-scheme</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/guardant-health-ordered-to-pay-245mn-in-dna-sequencing-patent-dispute</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/argenx-soars-on-trial-success-as-europes-biotech-champion-mounts-record-breaking-rally</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/kimberly-clark-seeks-eu-clearance-for-40bn-kenvue-acquisition</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-approves-gileads-once-daily-combination-pill-for-suppressed-hiv-patients</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/white-house-strikes-second-round-of-most-favored-nation-drug-pricing-deals-with-nine-mid-sized-pharmaceutical-companies</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-clears-roche-and-eli-lillys-blood-test-for-alzheimers-detection</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eli-lilly-launches-oral-weight-loss-pill-foundayo-in-the-uk</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/celon-pharmas-generic-semaglutide-matches-ozempic-in-early-trial-sending-shares-surging</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alnylam-cuts-full-year-sales-forecast-as-post-launch-ttr-drug-momentum-fades</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/pfizer-grapples-with-post-covid-hangover-as-debt-and-doubts-mount</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eu-regulators-cite-data-manipulation-in-tavneos-market-withdrawal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/nestl-bets-on-glp-1-side-effects-as-next-nutrition-frontier</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/karyopharm-faces-default-as-cash-reserves-dwindle-to-four-week-runway</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sandoz-strikes-77mn-upfront-deal-with-henlius-for-three-biosimilar-drugs</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alnylam-investors-face-securities-fraud-probe-after-shares-plunge-on-guidance-cut</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/lilly-files-six-lawsuits-over-illegal-sales-of-unapproved-obesity-drug-retatrutide</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-grants-accelerated-approval-to-bristol-myers-squibbs-oral-multiple-myeloma-treatment</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bristol-myers-faces-renewed-67bn-lawsuit-over-celgene-deal-milestones</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-halts-lung-cancer-study-in-latest-blow-to-pipeline</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/jazz-pharmaceuticals-strikes-132bn-deal-for-actio-biosciences-to-expand-epilepsy-franchise</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/hims-amp-hers-swings-to-wider-loss-as-branded-obesity-drugs-weigh-on-margins</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/cardinal-health-lifts-profit-outlook-on-specialty-drug-momentum</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebios-attruby-nears-blockbuster-status-as-attr-market-tilts-toward-stabilizers</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/tenax-heart-drug-fails-late-stage-trial-shares-collapse-nearly-90</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/exor-cleared-to-raise-philips-stake-to-22-under-revised-shareholder-agreement</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/four-pharma-franchises-stumble-despite-blockbuster-status</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-moves-to-tighten-oversight-of-food-additives</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/zydus-lifesciences-quarterly-profit-falls-sharply-as-costs-surge</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alcon-lifts-margin-outlook-as-tariff-refunds-boost-profitability-forecast</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/curium-strikes-deal-worth-up-to-8bn-to-acquire-lantheus-in-radiopharmaceutical-sector-consolidation</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/california-supreme-court-hands-gilead-landmark-victory-in-hiv-drug-innovation-case</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/kkr-to-take-integer-holdings-private-in-57bn-all-cash-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/supernus-and-indivior-merge-in-all-stock-deal-to-create-cns-focused-biopharma</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/abbvie-trims-full-year-profit-outlook-on-apogee-deal-while-beating-second-quarter-estimates</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/vertex-lifts-revenue-guidance-as-cystic-fibrosis-franchise-drives-strong-second-quarter</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/moderna-beats-revenue-estimates-as-investors-await-pivotal-fda-flu-vaccine-ruling</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-investors-balk-at-prospect-of-near-400bn-bristol-myers-tie-up</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/merck-strikes-early-licensing-deals-for-experimental-hiv-pill-in-developing-world</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alnylam-shares-touch-52-week-low-as-biotech-sell-off-weighs-on-rnai-pioneer</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/number-of-confirmed-ebola-cases-rises-to-3200-including-1405-deaths-congo-says</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazenecas-ultomiris-fails-late-stage-trial-in-rare-transplant-complication</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novo-nordisk-seeks-court-order-to-halt-eli-lilly-obesity-drug-ads</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/cipla-posts-third-straight-quarterly-profit-decline-names-veteran-dinesh-jain-as-cfo</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/west-pharma-lifts-profit-outlook-as-glp-1-drug-boom-drives-injectable-components-demand</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/amgen-submits-real-world-patient-data-in-bid-to-save-tavneos-from-fda-withdrawal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-wins-fda-filing-acceptance-for-rare-calcium-disorder-drug</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/argenx-to-acquire-forte-biosciences-for-22bn-in-autoimmune-push</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/roche-launches-prevention-trial-for-alzheimers-antibody-in-race-with-lilly</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-licenses-chinese-lung-cancer-drug-in-600mn-upfront-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/biogens-anti-tau-alzheimers-drug-shows-mixed-but-encouraging-results-in-mid-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/taco-bell-removes-menu-items-amid-widening-us-cyclosporiasis-outbreak</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/insulet-partners-with-calm-to-address-mental-health-burden-of-diabetes-management</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-approves-celcuitys-gedatolisib-for-advanced-breast-cancer-in-first-commercial-win</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-shares-hit-52-week-high-as-astrazeneca-trial-failure-boosts-rival-drugs-prospects</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/gsk-to-seek-fda-approval-for-jemperli-in-rectal-cancer-after-phase-2-success</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-sued-over-policy-allowing-unauthorized-vaping-products-to-remain-on-sale</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-approves-vertexs-casgevy-for-children-as-young-as-2-opening-door-to-thousands-more-patients</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/congo-begins-trial-of-gileads-gild-experimental-antiviral-for-ebola-bundibugyo</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/lonza-lonzs-expanded-adc-manufacturing-capacity-and-broadened-partnership-with-unnamed-us-drugmaker</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-bbio-touted-kidney-protective-data-for-attruby-differentiating-it-from-attr-cm-rivals</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-aznl-signed-177bn-kidney-disease-drug-discovery-deal-with-cspcnbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-pharma-bbio-climbed-75-in-a-year-as-pipeline-optimism-fueled-investor-confidence-1</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ares-management-ares-portfolio-company-aspen-group-abandoned-wellnow-sale-as-debt-pressure-mounted</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-novns-agreed-15bn-acquisition-of-uk-biotech-myricx-bio</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/amgen-amgn-won-court-order-blocking-colorados-enbrel-price-cap</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/viridian-wins-fda-approval-for-thyroid-eye-disease-drug-setting-up-clash-with-amgen</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/scottish-women-launch-legal-action-against-pfizer-over-contraceptive-injection-linked-to-brain-tumors</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/nejm-retracts-study-behind-amgens-tavneos-approval-after-fda-finds-altered-data</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-rejects-sobis-gout-drug-over-manufacturing-concerns-leaving-amgens-krystexxa-unchallenged</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/hc-wainwright-trims-alnylam-price-target-despite-bullish-long-term-rnai-outlook</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/brussels-opens-formal-antitrust-case-against-sanofi-over-flu-vaccine-marketing</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/zymeworks-to-buy-theravance-biopharma-in-929mn-cash-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/pfizer-and-innovent-glp-1-drugs-clear-preliminary-hurdle-for-china-insurance-list</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-picks-lilly-regeneron-for-fast-track-manufacturing-review-program</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/m8nah0wkbyijz9zf5a92mi7721nfeq</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/whistleblower-lawsuit-accuses-novartis-and-genentech-of-decades-long-kickback-scheme-over-xolair</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebios-oral-achondroplasia-drug-shows-growth-and-body-proportionality-gains-in-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/uk-antitrust-watchdog-secures-reversal-in-pfizer-epilepsy-drug-pricing-case</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/mercks-anti-tl1a-drug-hits-main-goal-in-ulcerative-colitis-trial-though-data-gaps-temper-analyst-enthusiasm</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/south-africa-court-blocks-compounded-ozempic-copies-in-novo-nordisk-case</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/abbvie-deepens-immunology-push-with-109bn-apogee-swoop</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/kardigan-surges-in-nasdaq-debut-after-upsized-400mn-ipo</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-reverses-course-on-regenxbios-rare-disease-gene-therapy-backs-accelerated-approval-path</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/pfizers-experimental-lung-cancer-drug-fails-to-extend-survival-in-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alnylam-reprimanded-over-amvuttra-promotion-after-pfizer-complaint-to-uk-watchdog</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novo-nordisk-to-seek-wegovy-pill-approval-in-china-within-months</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/nara-organics-recalls-us-infant-formula-after-botulism-cases-linked-to-product</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/byqrv47f6ehqk2m49trn51q8b687g9</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/activist-investor-builds-stake-in-bio-techne-pushes-for-sale</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/jazz-pharmaceuticals-lung-cancer-drug-fails-phase-3-trial-in-fresh-setback-for-accelerated-approval</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alnylam-pharmaceuticals-shares-hit-fresh-low-as-stock-slides-27-this-year</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-clears-first-over-the-counter-glucose-monitor-for-children</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-approves-wider-use-of-sanofis-tzield-in-newly-diagnosed-type-1-diabetes-patients</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/spyres-bowel-disease-drug-meets-goals-in-mid-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/mrna-cancer-vaccines-show-durable-results-in-melanoma-early-promise-in-harder-to-treat-tumors</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/elicio-therapeutics-shares-plunge-72-after-pancreatic-cancer-vaccine-misses-mid-stage-trial-goal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/synthetic-opioids-add-to-europes-drug-dangers-as-market-shifts-eu-agency-warns</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sanofi-halts-phase-3-trial-of-riliprubart-after-interim-data-disappoint</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-reprimanded-again-over-employee-linkedin-activity</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ai-saves-clinicians-time-but-training-gaps-persist-philips-survey-finds</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/pfizer-faces-surge-in-depo-provera-brain-tumor-lawsuits-ahead-of-pivotal-hearing</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-investigates-mifepristone-safety-as-anti-abortion-pressure-on-trump-mounts</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/h1ehwpmlnc34ytpf11iypso4ybcwp4</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alzecure-strikes-lilly-deal-worth-over-1bn-for-alzheimers-drug-candidate</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/indian-cancer-patients-face-shortage-of-key-chemotherapy-drugs-as-platinum-prices-surge</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/state-bank-of-india-plans-1bn-funding-commitment-for-sun-pharmas-organon-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/gileads-trodelvy-suffers-fresh-setback-in-lung-cancer-trial-clearing-path-for-rivals</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/zealand-pharma-shares-slide-as-obesity-drug-trial-reveals-high-dropout-rate</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/gsk-bets-106-billion-on-cancer-with-nuvalent-takeover</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/centene-offers-staff-buyouts-after-obamacare-enrollment-slump</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/roche-reaffirms-german-investment-plans-as-rivals-retreat</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alzheimers-drug-pipeline-broadens-beyond-amyloid-as-researchers-pursue-new-targets</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/uk-reviews-palantir-nhs-contract-amid-pressure-to-trigger-break-clause</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/lilly-shares-climb-as-next-generation-obesity-drug-data-cements-market-lead</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/cholera-outbreak-kills-74-in-nigerias-borno-state-as-cases-surpass-7800</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/us-brand-name-drug-prices-climb-after-launch-while-falling-abroad-aarp-finds</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/massachusetts-sues-unitedhealth-unit-over-alleged-100mn-medicaid-fraud</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eli-lilly-strikes-three-vaccine-deals-worth-up-to-4-billion</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ucb-trial-puts-bimzelx-ahead-of-abbvie-rival-in-arthritis-duel</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/drugmakers-race-to-find-weapons-against-rare-ebola-strain-as-congo-toll-mounts</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/pharma-bets-big-on-cancer-bispecifics-but-may-be-targeting-the-wrong-tumour</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/aribio-receives-first-tranche-of-fosun-pharma-payment-in-alzheimers-licensing-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/biopharma-mampa-on-pace-for-best-year-since-pre-pandemic-peak</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/abbvie-to-cut-85-jobs-at-california-eye-care-unit</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-aznl-valuation-debate-intensified-as-investors-weighed-pipeline-growth-against-pricing-risks</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ema-backs-novo-nordisks-wegovy-pill-in-boost-for-oral-weight-loss-race</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astellas-bets-on-newer-drug-portfolio-to-power-profit-growth-through-2030</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/glp-1-drugs-show-promising-signs-of-slowing-cancer-progression</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eu-regulator-backs-astrazeneca-breast-cancer-pill-amid-us-divide</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/lilly-lly-mounjaro-outperformed-rival-glp-1-therapies-in-early-type-2-diabetes-studynbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bristol-myers-squibb-bmy-multiple-myeloma-drug-cut-progression-risk-in-late-stage-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sun-pharmaceutical-beats-profit-forecasts-but-shares-fall-as-costs-weigh-on-margins</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-pharma-shares-rise-on-regulatory-filing-and-rare-disease-trial-data</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-and-daiichi-sankyo-win-fda-approval-for-datroway-in-breast-cancer-edging-ahead-of-gilead</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/guggenheim-backs-avalyn-pharma-with-buy-rating-on-inhaled-fibrosis-pipeline</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/nestl-and-danone-face-scrutiny-over-infant-formula-toxin-recall-timeline</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/cmhdzhyp0hcwup0v1hzym0vvb8eora</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/roche-opens-door-to-generic-production-of-xofluza-in-developing-world</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-novns-terminated-porton-manufacturing-deal-and-warned-of-potential-64m-legal-claims</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/biomarin-bmrn-rare-disease-drug-missed-key-phase-3-goal-raising-approval-concerns</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/us-supreme-court-rejected-pharma-industry-challenge-to-medicare-drug-pricing-law</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-aznl-secured-fda-approval-for-blood-pressure-drug-baxfendy</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/merck-nyse-mrk-uterine-cancer-drug-met-late-stage-goals-boosting-investor-focus-on-adc-pipeline</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/white-house-expands-drug-pricing-portal-with-600-generic-medicines</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eli-lilly-claims-double-crown-in-pharma-rampd-rankings</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/who-rushes-supplies-to-congo-as-ebola-outbreak-spreads-amid-deepening-uncertainty</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/habra5kpj1j2qbjzbufxleyyfqydju</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/iwa8ixsiqugjhl1m5t4hwcslbbv5ru</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-presses-challenge-to-pfizer-in-attr-cm-after-data-hint-at-survival-edge</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sanofi-deepens-rare-disease-push-with-diagnostic-and-treatment-partnerships</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novo-nordisk-heart-drug-disappoints-in-key-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/rocket-pharmaceuticals-stretches-cash-runway-as-priority-review-voucher-sale-offsets-clinical-setbacks</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/jazz-pharmaceuticals-confounds-sceptics-with-strong-q1-print-but-valuation-now-leaves-little-room-for-error</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/algeria-and-hungary-deepen-pharmaceutical-ties-in-latest-sign-of-algiers-industrial-outreach</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/atyr-pharma-nasdaq-atyr-shares-fell-after-company-outlined-revised-phase-3-trial-strategy</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/brano-therapeutics-secured-68m-seed-funding-to-advance-heart-failure-pipeline</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/zealand-pharma-cph-zeal-shares-rose-after-obesity-pipeline-progress-and-roche-linked-outlook-boost</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/nigerias-neimeth-posts-strong-q1-revenue-gains-but-debt-costs-cloud-the-recovery</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/kazakhstan-greenlights-80mn-pharmaceutical-plant-in-latest-push-for-domestic-drug-self-sufficiency</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/german-healthcare-reforms-raised-pressure-on-pharma-and-hospital-stocks-as-berlin-targeted-40bn-deficit</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/acadia-chief-warns-trump-most-favoured-nation-policy-threatens-global-drug-rampd-partnerships</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/takeda-to-cut-4500-jobs-as-it-steps-up-restructuring-drive</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-commissioner-makary-resigns-amid-white-house-pressure-and-flavoured-vape-dispute</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/rigel-pays-85mn-for-global-rights-to-first-fda-approved-protein-degrader-in-breast-cancer</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/milestones-cardamyst-launch-gains-early-traction-as-cardiovascular-biotech-ramps-spending</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/micro-cap-mira-pharmaceuticals-publishes-early-data-on-obesity-and-addiction-drug-candidate</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eli-lilly-halts-india-obesity-campaign-after-regulatory-warning</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eu-agrees-medicines-stockpiling-law-to-prevent-repeat-of-pandemic-shortages</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/polpharma-launches-270mn-bid-for-romanias-biofarm-in-central-european-consolidation-push</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/gsk-turns-to-sino-biopharma-to-push-hepatitis-b-functional-cure-into-chinese-market</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fine-foods-analysts-trim-earnings-forecasts-after-q1-print-as-shares-slide-14</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/former-novartis-compliance-attorney-revives-whistleblower-claims-in-new-jersey-appeal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/capricor-sues-ns-pharma-over-duchenne-therapy-distribution-dispute</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/dc-circuit-appears-sceptical-of-teva-challenge-in-medicare-drug-pricing-fight</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alto-neuroscience-pushes-back-against-investor-claims-over-depression-drug-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/french-court-allows-velcade-damages-dispute-to-proceed-against-generic-drugmakers</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-steps-up-action-on-drug-advertising-and-targets-amvuttra</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sun-pharma-secures-interim-win-in-trademark-dispute</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-and-sandoz-face-ongoing-antitrust-pressure-in-us-generics-case</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/california-court-signals-limits-on-duty-to-innovate-in-gilead-hiv-case</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novo-nordisks-pill-is-selling-whether-that-is-enough-to-catch-eli-lilly-is-another-matter</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/faron-pharmaceuticals-scraps-lago-kapital-liquidity-deal-as-natural-trading-volumes-pick-up</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/arrowhead-shares-jump-as-australia-clears-first-in-class-therapy-for-ultra-rare-lipid-disorder</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/texas-to-receive-286mn-as-purdue-pharmas-74bn-opioid-settlement-takes-effect</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/jazz-pharmaceuticals-heads-into-q1-with-sector-tailwind-but-recent-guidance-miss-casts-shadow</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alnylam-shares-lag-despite-q1-profit-breakthrough-as-rnai-pioneers-valuation-divides-wall-street</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novo-nordisk-challenges-antitrust-claims-in-glp-1-casenbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/jury-deliberates-in-opioid-overdose-malpractice-casenbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/astrazeneca-commits-300m-to-uk-sites-after-paused-projectsnbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/sun-pharma-to-acquire-organon-in-1175b-dealnbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/navigating-trumps-new-pharmaceutical-tariffsnbspnbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-national-priority-vouchers-for-psychedelicsnbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/supreme-court-examines-limits-of-skinny-label-marketing-in-hikma-casenbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/update-oregon-to-receive-656m-under-purdue-pharma-opioid-settlementnbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/judge-dismisses-key-claims-in-eli-lilly-lawsuit-against-empower-pharmacynbsp</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/supremenbspcourt-case-on-fish-oil-drug-could-impact-generic-drug-prices</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/merz-wins-appeal-to-block-generic-ms-drug-sales-in-france</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/malaysian-court-rejects-bid-to-challenge-pharmaceutical-tender-decision</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/purdue-pharma-sentenced-to-55-billion-as-court-clears-path-for-opioid-settlement</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/federal-judge-rules-north-dakota-drug-access-law-unconstitutional</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/boehringer-ingelheim-reports-166-weight-loss-in-late-stage-trial-of-obesity-drug</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ligand-to-acquire-xoma-royalty-for-739mn-in-deal-that-doubles-biotech-royalty-portfolio</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/jazz-pharmaceuticals-ziihera-wins-fda-priority-review-for-first-line-gastric-cancer-use</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/catalyst-pharmaceuticals-draws-italian-buyer-interest-as-us-rare-disease-assets-fetch-premium</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/breaking-pfizer-settles-vyndamax-tafamidis-suit</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/wall-street-downgrades-terns-pharmaceuticals-as-merck-swoops-on-67bn-cancer-drug-bet</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novartis-wins-eu-green-light-for-rhapsido-in-chronic-urticaria-opening-front-in-oral-immunology-drugs</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/hikma-pharmaceuticals-no-longer-appears-to-be-challenging-the-validity-of-pfizers-patent</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/big-pharma-names-sit-on-uk-panel-shaping-fallout-from-us-uk-drugs-trade-pact</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/ionis-rally-raises-questions-over-valuation-after-strong-run</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/eli-lilly-strikes-63bn-deal-for-centessa-to-bolster-neuroscience-pipeline</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/t3xs2xkoya14xqnkq8zsbgkqvban7t</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/trump-secures-final-drug-pricing-accord-with-regeneron</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/new-catalytic-method-promises-more-efficient-route-to-amine-synthesis</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/branded-generics-gain-ground-as-drugmakers-balance-cost-and-trust</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/tafamidis-trial-analysts-say-early-signals-point-to-pfizer-pfe-win-upside-for-bridgebio-bbio-downside-for-generics-manufacturers</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/south-korea-climbs-to-third-in-global-drug-development-pipeline</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/lilly-rejects-subsidised-listing-for-diabetes-drug-amid-pricing-dispute</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/iran-war-drives-up-cost-of-paracetamol-and-hay-fever-drugs-by-up-to-30-in-england</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/amneal-pharmaceuticals-to-acquire-kashiv-biosciences-in-11bn-deal</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/abbvie-to-invest-14bn-in-north-carolina-pharmaceutical-campus</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/us-investor-heights-capital-holds-25-of-faron-pharmaceuticals-through-shares-and-convertible-bonds</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/pfizer-set-to-defend-tafamidis-franchise-as-generics-challenge-threatens-165bn-heart-drug-market</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/europe-at-critical-juncture-as-trump-drug-pricing-policy-curbs-new-medicine-launches</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/adial-clears-manufacturing-hurdle-for-ad04-alcohol-use-disorder-drug-ahead-of-phase-3-trial</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/indiana-pharma-research-group-to-present-crystallinity-research-at-basel-synchrotron-workshop</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/belpointe-opens-174mn-stake-in-regeneron-as-biotech-rides-earnings-beat</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/agios-shares-slide-25-as-novo-nordisk-sickle-cell-data-rattles-rival-drug-programme</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/york-biotech-wins-state-funding-to-turn-pharma-waste-into-recyclable-packaging</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/uk-filtration-group-amazon-filters-targets-pharma-buyers-at-copenhagen-industry-summit</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/south-koreas-olix-teams-up-with-ai-drug-design-group-galux-on-next-generation-sirna-therapies</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/us-food-and-drug-administration-to-convene-expert-panel-on-wider-access-to-peptides</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-accelerated-approval-pathway-lacks-transparency-influential-pricing-body-warns</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/alamar-biosciences-raises-191mn-in-upsized-ipo-as-healthcare-listings-gather-pace</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/morocco-eu-pharma-trade-gap-widens-as-bloc-posts-record-surplus</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/middle-east-conflict-threatens-pharma-supply-chains-and-drives-cost-pressures</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/us-imposes-sweeping-pharma-tariffs-under-section-232-order</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/telix-raises-600mn-in-upsized-convertible-bond-offering</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novo-nordisk-weight-loss-drug-shows-liver-benefits-in-mouse-study</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/merck-to-acquire-terns-for-67bn-in-push-to-offset-keytruda-patent-loss</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/pharma-procurement-blindsided-as-supply-shocks-expose-data-gap</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/novo-nordisk-taps-openai-to-embed-artificial-intelligence-across-drug-pipeline</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-rebukes-pfizer-over-misleading-adcetris-social-media-ads</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/fda-clears-first-generics-of-astrazenecas-farxiga-opening-85bn-market-to-rivals</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/latest-news/bridgebio-chief-sells-59mn-in-shares-under-pre-arranged-plan</loc><lastmod>2026-11-16T12:23:34.000Z</lastmod></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/abbvie</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/alnylam-pharmaceuticals</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/amgen</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/argenx</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/astellas</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/astrazeneca</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/bayer</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/biogen</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/biontech</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/boehringer-ingelheim</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/bridgebio-pharma</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/bristol-myers-squibb</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/chugai-pharmaceutical</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/csl</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/daiichi-sankyo</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/eli-lilly</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/exelixis</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/genmab</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/gilead-sciences</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/gsk</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/halozyme</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/insmed</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/ionis-pharmaceuticals</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/johnson-johnson</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/madrigal-pharmaceuticals</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/merck-co</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/moderna</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/neurocrine-biosciences</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/novartis</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/novo-nordisk</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/pfizer</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/regeneron</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/roche</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/sanofi</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/shionogi</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/sobi</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/takeda</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/teva</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
<url><loc>https://www.pharmawire.org/pharma-biotech-company-faqs/vertex-pharmaceuticals</loc><changefreq>monthly</changefreq><priority>0.7</priority></url>
</urlset>